Drug Profile
TRC 093
Alternative Names: D-93; MT293; TRC-093Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Micromet Inc
- Developer TRACON Pharmaceuticals
- Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Collagen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (IV)
- 19 Nov 2009 Preclinical pharmacodynamics data presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)